Featured · Health
Novo's pill keeps winning switchers while the payers behind its volume math walk out
Novo's first real-world switch study, presented 30 September, shows patients trading Wegovy and Zepbound injections for the daily pill kept losing weight. The subsidized exchanges that growth leans on are thinning for 2027: Molina shrinks to six states, Cigna leaves all eleven.
· 3 min read
